Payment overview · 2025
General Payments
$819.50
21 reported records · 7 companies
Healthcare provider profile · identity verified
Labronz C Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, OH · NPI 1003857749
Verified facts
What the public records show
CMS Open Payments records show Labronz C Davis, MD received $819.50 in general payments during 2025 across 21 reported records.
Boston Scientific Corporation accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $233.15 | 28.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $135.80 | 16.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.39 | 15.1% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $121.93 | 14.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.57 | 14.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.16 | 8.7% | 4 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $18.50 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $819.50 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $233.15 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $135.80 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $123.39 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $121.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $115.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.16 | 4 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 156 |
| Gabapentin | Gabapentin | 362 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 338 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 74 |
| Omeprazole | Omeprazole | 269 | 66 |
| Ibuprofen | Ibuprofen | 260 | 70 |
| Metformin Hcl | Metformin Hcl | 244 | 54 |
| Simvastatin | Simvastatin | 162 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 156 | 39 |
| Carvedilol | Carvedilol | 152 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 40 |
| Ozempic | Semaglutide | 148 | 21 |
| Lisinopril | Lisinopril | 146 | 39 |
| Trazodone Hcl | Trazodone Hcl | 142 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 123 | 24 |
| Losartan Potassium | Losartan Potassium | 117 | 32 |
| Prednisone | Prednisone | 117 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 35 |
| Allopurinol | Allopurinol | 107 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 31 |
| Methylprednisolone | Methylprednisolone | 105 | 56 |
| Azithromycin | Azithromycin | 98 | 64 |
| Meloxicam | Meloxicam | 97 | 29 |
| Furosemide | Furosemide | 79 | 20 |
| Chlorthalidone | Chlorthalidone | 77 | 23 |
| Finasteride | Finasteride | 77 | 27 |
| Meclizine Hcl | Meclizine Hcl | 76 | 22 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 75 | 18 |
| Eliquis | Apixaban | 73 | 20 |
| Sertraline Hcl | Sertraline Hcl | 71 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 23 |
| Famotidine | Famotidine | 70 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 58 | 15 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Glipizide | Glipizide | 55 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 12 |
| Colchicine | Colchicine | 54 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 19 |
| Linzess | Linaclotide | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Aripiprazole | Aripiprazole | 40 | 11 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 21 |
| Megestrol Acetate | Megestrol Acetate | 38 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 33 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 30 | 12 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Perphenazine | Perphenazine | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Atenolol | Atenolol | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $819.50 · 21 records | Boston Scientific Corporation | CHARTIS CATHETER, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, PULMONX CHARTIS TABLET CONSOLE, Veozah, WATCHMAN FLX, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error